Emyria delighted to be accepted into prestigious US pain initiative



Melbourne, Victoria - News Direct - 30 November 2022 -

PressReleaseTMPXyNU9Y.jpg


Emyria Ltd (ASX:EMD) Michael Winlo tells Proactive the company has been accepted into the US National Institute of Health's (NIH) Preclinical Screening Platform for Pain program. The NIH's National Institute of Neurological Disorders and Stroke (NINDS) — also the leading funder of neurological research in the US — will run the study as part of a broader initiative to stem the opioid public health crisis.
Hashtag: #Emyria

Penerbit bertanggung jawab penuh atas isi pengumuman ini
SUMBER:

Emyria Ltd

KATEGORI:

Business

 
DIPUBLIKASIKAN PADA:

30 Nov 2022

Hubungi Media OutReach hari ini

HUBUNGI KAMI SEKARANG